Browsing Tag
Granules Pharmaceuticals Inc
1 post
Granules India (NSE: GRANULES) exits FDA audit with four observations as regulatory scrutiny intensifies
Granules India's Chantilly facility exits a routine US FDA cGMP audit with four procedural Form 483 observations and no data integrity findings. Read what it means for the GRANULES growth outlook.